Indications
Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).
Composition
- Active substance
- inotersen sodium
- International name (INN)
- inotersen
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Tegsedi
- Active substance
- inotersen sodium
- ATC code
- N07
- Group
- Nervous system
- Therapeutic area
- Amyloidosis
- Marketing authorisation holder
- Akcea Therapeutics Ireland Limited
- Status
- Authorised
- EU authorisation